YTHDF1 Drives Asthma Inflammation Through Mitochondrial and Wnt Signaling
A new study links the RNA reader protein YTHDF1 to steroid-resistant asthma via mitochondrial dysfunction and β-catenin/TCF4 signaling.
Summary
Researchers identified YTHDF1, a protein that reads m6A RNA modifications, as a key driver of allergic airway inflammation and mitochondrial dysfunction in a mouse model of steroid-insensitive asthma. Using chemical inhibitors and two asthma models (TDI and house dust mite), the team showed that blocking YTHDF1 activity at low doses reduced airway inflammation and mitochondrial damage. The β-catenin/TCF4 signaling pathway was found to regulate YTHDF1 gene expression, and inhibiting this pathway reduced both inflammation and YTHDF1 levels. A mitochondria-stabilizing drug (SS-31) also curbed inflammation, reinforcing the mitochondrial connection. These findings point to YTHDF1 and its upstream regulators as potential therapeutic targets for hard-to-treat asthma.
Detailed Summary
Steroid-insensitive asthma represents one of the most challenging subtypes of the disease, leaving many patients without effective treatment options. Understanding the molecular mechanisms that drive this form of airway inflammation is critical for developing new therapies. This study focuses on the role of YTHDF1, a reader protein for N6-methyladenosine (m6A) RNA modifications, in toluene diisocyanate (TDI)-induced asthma, a well-established model of occupational, steroid-resistant asthma.
Researchers sensitized and challenged mice with TDI or house dust mite (HDM) allergens to create asthma models. They then tested three interventions: Tegaserod (an m6A/YTHDF1 inhibitor), LF3 (a β-catenin/TCF4 inhibitor), and SS-31 triacetate (a mitochondrial stabilizer). Human bronchial epithelial cells and macrophages were also exposed to TDI to model the human airway environment.
YTHDF1 was found to be upregulated in TDI-induced asthmatic mice. Notably, low-dose Tegaserod (1 mg/kg) significantly reduced airway hyperresponsiveness, inflammation, remodeling, and mitochondrial dysfunction, while the higher dose (5 mg/kg) paradoxically worsened outcomes — a dose-dependent biphasic effect that warrants further investigation. Using bioinformatics (JASPAR), the team predicted that TCF4, a downstream transcription factor of β-catenin, binds to the YTHDF1 promoter. Blocking the β-catenin/TCF4 pathway with LF3 reduced YTHDF1 expression, airway inflammation, and mitochondrial damage, confirming the regulatory axis. SS-31 further validated mitochondrial dysfunction as a central mechanism in this inflammatory cascade.
These findings establish a novel YTHDF1–β-catenin/TCF4–mitochondria axis in allergic airway inflammation. Targeting this pathway could open new avenues for treating steroid-resistant asthma, though translation to clinical practice will require human validation and resolution of the dose-response paradox observed with YTHDF1 inhibition.
Key Findings
- YTHDF1 is upregulated in TDI-induced steroid-insensitive asthma models in mice.
- Low-dose Tegaserod (1 mg/kg) reduced airway inflammation and mitochondrial dysfunction; high dose worsened outcomes.
- β-catenin/TCF4 signaling transcriptionally regulates YTHDF1 expression via promoter binding.
- Blocking β-catenin/TCF4 with LF3 reduced YTHDF1 levels, inflammation, and mitochondrial damage.
- Mitochondria-stabilizing drug SS-31 independently reduced TDI-induced airway inflammation.
Methodology
Mouse models used TDI and HDM sensitization/challenge protocols alongside in vitro human bronchial epithelial cell and macrophage exposures. Three pharmacological interventions (Tegaserod, LF3, SS-31) were tested, and JASPAR bioinformatics software was used to predict TCF4 binding at the YTHDF1 promoter. The study is preclinical and does not include human clinical data.
Study Limitations
The study is entirely preclinical, relying on mouse models and cell cultures without human clinical validation. The paradoxical worsening of asthma at high-dose Tegaserod is unexplained and raises safety questions for therapeutic development. Findings from TDI-induced occupational asthma models may not generalize to all asthma subtypes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.